Adoptive immunotherapy in patients with malignant glioma
Yoshida, S.; Takai, N.; Saito, T.; Tanaka, R.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(6 Part 1): 1930-1932
1987
ISSN/ISBN: 0385-0684 PMID: 3496052 Document Number: 297212
We report preliminary results of adoptive immunotherapy in 12 patients with malignant glioma. The patients received both 1.8 to 20 X 10(8) autologous lymphokine activated killer (LAK) cells, and 8 to 16 X 10(4) units of interleukin-2. Objective regression of the tumor was observed in 8 patients. In 4 cases, the size of the tumor was remarkably reduced. No severe side effects were observed. Furthermore, LAK cells and their precursor cells were serologically studied.